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Abstract
Interleukin-7 (IL-7) is an essential cytokine for lymphocyte growth that has the potential for promoting immune
reconstitution. This feature makes IL-7 an ideal candidate for therapeutic development. As with other cytokines, signaling
through the IL-7 receptor induces the JAK/STAT pathway. However, the broad scope of IL-7 regulatory targets likely
necessitates the use of other signaling components whose identities remain poorly defined. To this end, we used an IL-7
dependent T-cell line to examine how expression of the glycolytic enzyme, Hexokinase II (HXKII) was regulated by IL-7 in a
STAT5-independent manner. Our studies revealed that IL-7 promoted the activity of JNK (Jun N-terminal Kinase), and that
JNK, in turn, drove the expression of JunD, a component of the Activating Protein 1 (AP-1) transcription factors. Gel shifts
showed that the AP-1 complex induced by IL-7 contained JunD but not c-Fos or c-Jun. Inhibition of JNK/JunD blocked
glucose uptake and HXKII gene expression, indicating that this pathway was responsible for promoting HXKII expression.
Because others had shown that JunD was a negative regulator of cell growth, we performed a bioinformatics analysis to
uncover possible JunD-regulated gene targets. Our search revealed that JunD could control the expression of proteins
involved in signal transduction, cell survival and metabolism. One of these growth promoters was the oncogene, Pim-1.
Pim-1 is an IL-7-induced protein that was inhibited when the activities of JNK or JunD were blocked, showing that in IL-7
dependent T-cells JunD can promote positive signals transduced through Pim-1. This was confirmed when the IL-7-induced
proliferation of CD8 T-cells was impaired upon JunD inhibition. These results show that engagement of the IL-7 receptor
drives a signal that is more complex than the JAK/STAT pathway, activating JNK and JunD to induce rapid growth
stimulation through the expression of metabolic and signaling factors like HXKII and Pim-1.
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Introduction
Interleukin-7 (IL-7) plays a major role in lymphocyte survival,
development and proliferation [1]. Because of its importance as a
lymphocyte growth factor, IL-7 has potential use as a therapeutic
agent in cancer therapy [2], bone marrow transplantation [3] and
treatment of infectious diseases like sepsis [4] and HIV [5]. IL-7 is
a 25 kDa protein that is not produced by lymphocytes but was
discovered as a product of a thymic stromal cell line [6]. Tissues
that produce IL-7 include the generative lymphoid organs [7,8];
however, the regulation of IL-7 production remains unclear but
could be induced in nonlymphoid tissues upon infection [9]. The
receptor for IL-7 (IL-7R), expressed by lymphocytes, consists of
the IL-7Ra chain and the common cytokine c chain (cc) [10].
Upon binding of IL-7, the two receptor chains heterodimerize and
initiate signaling mediated through receptor-associated kinases,
Janus kinases, Jak1/Jak3, which phosphorylate and activate the
transcription factor, STAT5a/b [1]. The most recent biological
information on IL-7 signal transduction focuses on the JAK/
STAT pathway, with scant new information on probable crosstalk
with other signaling pathways.
Descriptions of the IL-7R interacting with Fyn or Lyn were
published in the early 1990’s [11,12], while other early work
revealed aspects of Mitogen Activated Protein Kinase (MAPK)
signaling in the context of IL-7 [13,14]. Lck-mediated T-cell
receptor (TCR) signaling was shown to both synergize and operate
independently of IL-7 signaling to promote T-cell proliferation
[15]. We found that inhibition of Lck modulated the IL-7 dose
response of CD4 but not CD8 T-cells by regulating the activation
of STAT5 [16]. In regards to the MAPKs, IL-7 could induce T
cell proliferation in the absence of ERK (Extracellular signal-
Regulated Kinase) activity [13] but required p38 MAPK [14]. In
contrast, we and others reported that IL-7 withdrawal induced the
activity of p38 MAPK and JNK (Jun N-terminal Kinase) and
promoted apoptosis [17,18] as well as cell cycle arrest [19]. How
MAPKs, like p38 MAPK and JNK, can have both growth-
promoting and apoptotic functions that are controlled by IL-7
remains unknown.
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translational regulation of Activating Protein 1 (AP-1) transcription
factors. AP-1 are dimeric transcription factors composed of
proteins with basic leucine zipper domains needed for dimer
formation and DNA-binding [20]. The major subfamilies that
form AP-1 are Jun (c-Jun, JunB and JunD) and Fos (c-Fos, FosB,
Fra1 and Fra2). Activating Transcription Factor (ATF) proteins
and Maf proteins can also be components [21]. The potential for
multiple combinations gives the AP-1 family its specificity and
capacity for a large repertoire of regulated-genes [22]. The activity
of AP-1 is mediated in part by ERK, JNK, or FRK (Fyn-Related
Kinase) - each of these kinases phosphorylates different substrates.
Three distinct JNK gene families have been described: JNK1,
JNK2, and JNK3. JNK1 and 2 are ubiquitously expressed, while
JNK3 is selectively expressed in neuronal and cardiac tissues [23].
The Jun family is activated through phosphorylation by JNKs,
with c-Jun and JunD being recognized targets [24]. While c-Jun
and JunB are considered activating factors and expressed as early
genes [25–27], JunD was first described as a negative regulator of
cell proliferation [28–30].
There exists a number of IL-7 functional targets [31]. To
name a few, IL-7 promotes cell survival through Bcl-2
upregulation and repression of Bax [32–34], Bim [35] or Bad
[36]. IL-7 drives proliferation through cell cycle regulators such
as Cdc25A [19] and p27 kip [37]. IL-7 also regulates glucose
metabolism [34,38], and this function is partially fulfilled through
transcriptional control of Hexokinase II (HXKII) [39]. How
other signaling pathways augment the JAK/STAT signal and
contribute to T-cell growth is unknown. In this study, we
investigated the activity of the JNK pathway in IL-7- dependent
T-cells and found that it involved the activation of JunD-
containing AP-1 complexes. JunD/AP-1 drove the expression of
HXKII. Using a bioinformatics approach, we discovered other
JunD-regulated genes that included the oncogene, Pim-1, which
was induced by IL-7. The importance of these findings is the
demonstration that, in T-cells, JunD can modulate positive
growth in response to IL-7, enhancing the initial cytokine signal
transduced by JAK/STAT.
Results
Previously, using an IL-7 dependent T-cell line, D1, and
primary T-cells, we reported that HXKII gene expression was
regulated by an IL-7 signal [39]. However, we found that
inhibition of STAT5 did not prevent the expression of HXKII in
response to IL-7 (Fig. S1). To demonstrate that a STAT5-
independent, but still an IL-7 dependent signal, controlled HXKII
gene expression, we nucleofected D1 cells with a chimeric IL-4/
IL-7 wild-type receptor or with a chimeric IL-4/IL-7 receptor
bearing a mutation in the STAT5 binding site, Y449. Normally,
when Y449 is phosphorylated it binds STAT5; therefore mutation
of this site would prevent STAT5 activation. D1 cells, nucleofected
with the chimeric receptors, were cultured with human IL-4. Gene
expression of HXKII was measured by quantitative PCR and
glucose uptake was measured by 2-DOG uptake. We found that
the IL-4-induced gene expression and glucose uptake in
nucleofected cells was not affected by the Y449 mutation and
that cells were comparable to those incubated with IL-7,
suggesting that these events were STAT5-independent (Fig. 1A).
Examination of the mouse HXKII promoter region showed that
the proximal promoter region contained most of the transcription
factors binding motifs that regulate HXKII expression [40]. Some
of the recognized factors included SP-1, NF-Y, CREB, Glucose
binding site, and the AP-1 complex. To study this, we examined
the activity of the MAPK pathway and induction of AP-1
transcription factors in response to IL-7.
JunD/AP-1 complexes are activated upon IL-7 stimulation
through the JNK Pathway
A limited number of studies showed that IL-7 withdrawal up-
regulated p38 MAPK [18] and JNK [17], and that ERK signaling
was dispensable in IL-7 dependent T-cells [13]. Because of the
importance of JNK in AP-1 activation [20], we examined JNK
activity in response to IL-7. Previously, we and others established
that D1 cells express all the known components of the IL-7 signaling
pathway and are representative of the primary T-cell response to
IL-7 [19,36,37,39,41,42]. Because of this and the fact that primary
T-cell subsets are not equally responsive to IL-7 [16,43], in the
current study we used D1 cells, which uniformly respond to the
cytokine, to study the functional outcomes of IL-7 signal
transduction. Our goal was to identify novel molecular events
driving the lymphoproliferative activity of IL-7. A JNK activity
assay was performed that involved immunoprecipitation of the
kinasefrom wholecelllysatesanddetectionofthephosphorylated c-
Jun substrate as a read out for kinase activity. As shown in the
immunoblot for phosphorylated c-Jun substrate in Figure 1B, D1
cells incubated with IL-7 had higher levels of JNK activity than
those deprived of IL-7 (Fig. 1B). In IL-7-deprived D1 cells, JNK
activity was initially observed through 6 hours of cytokine
withdrawal and was undetectable after 18 hours of cytokine
withdrawal. As control for protein input, JNK levels were detected
in lysates prior to immunoprecipitation. These results support that
JNK activation is a part of the IL-7 signaling pathway.
Since JNK is known to regulate the components involved in AP-
1 activation, a gel shift assay was performed to determine whether
IL-7 induced AP-1 DNA-binding activity. An oligonucleotide
probe containing the AP-1 DNA-binding consensus site was
incubated with nuclear extracts from D1 cells grown with or
without IL-7 for 18 hours. Shown in Figure 1C, EMSA results
revealed that more AP-1 bound to DNA in D1 cells incubated
with IL-7. This suggested that IL-7 induced the formation of AP-1
complexes that bound to the consensus DNA sequence. To
confirm specific binding of the protein to the AP-1 probe, a
competition assay with excess cold AP-1 probe (unlabeled) as well
as with a mutant AP-1 probe was performed. As seen in Figure 1C,
cold AP-1 probe effectively reduced binding of protein to the
radiolabeled AP-1 probe, while addition of mutant AP-1 probe
had little effect. To identify the components that formed the IL-7-
induced AP-1 complex, nuclear extracts, made from D1 cells
grown with IL-7, were co-incubated with supershift-specific
antibodies against c-Fos, c-Jun and JunD, and added to the AP-
1 radiolabeled DNA probe. We found that the c-Fos and c-Jun
antibodies did not produce a supershift or impede protein binding
to DNA, whereas the JunD antibody caused steric hindrance,
preventing protein binding to the AP-1 DNA probe (Fig. 1C). This
illustrates that IL-7 stimulation resulted in an AP-1 complex
containing JunD.
To determine whether the JNK pathway was involved in
synthesis and activation of JunD in response to IL-7, we examined,
by quantitative PCR, JunD gene expression levels in response to
IL-7 and in the presence of JNK (and, as control, p38 MAPK)
pharmacological inhibitors. Note that doses of inhibitors used were
experimentally determined. D1 cells were grown with or without
IL-7 for 18 hours, and, to a separate population of cytokine-
deprived cells, IL-7 was added back for 2 hours to induce
expression of IL-7-dependent gene products. Loss of IL-7 caused a
decrease in the gene expression of JunD that was restored upon a
two hour re-addition of IL-7 (Fig. 2A). This IL-7-driven increase in
JunD Promotes IL-7-Dependent Lymphocyte Growth
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32262Figure 1. IL-7 signaling induces JNK activity and promotes JunD-containing AP-1 complexes. (A) (Left panel) Quantitative PCR evaluation
of HXKII gene expression in the IL-7 dependent T-cell line, D1, after culture with or without IL-7. D1 cells were also nucleofected with a chimeric IL-4/
IL-7 receptor (IL-4/IL-7R WT), a chimeric IL-4/IL-7 receptor with a mutation in Y449 (IL4/IL7R Y449) or an empty vector (pcDNA), and stimulated with IL-
4, as described in Methods. (Right panel) In cells treated as described above, glucose uptake was assessed by measuring the accumulation of
radiolabeled 2-DOG as stated in Methods. (*) indicates a P value of ,0.05. (B) To assess JNK kinase activity in response to IL-7, a kinase assay was
performed. JNK was immunoprecipitated from whole cell lysates prepared from D1 cells cultured in the presence or absence of IL-7 for the times
indicated and the capacity to phosphorylate the kit-supplied substrate, c-Jun, measured as indicator of kinase activity. As input control, pre-
immunoprecipitation levels of JNK in lysates are shown. (C) Nuclear lysates prepared from D1 cells grown with or without IL-7 for 18 hours were
assayed for AP-1 complex binding to DNA by EMSA, using a radiolabeled DNA probe containing the AP-1 consensus binding site. Supershifts were
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p38 MAPK inhibitor (Fig. 2A). To confirm this result, protein
lysates from similarly treated cells revealed that JunD protein
decreased in the absence of IL-7 and increased upon IL-7 re-
addition (Fig. 2B) in the manner observed for the mRNA levels
(Fig. 2A). Inhibition of JNK caused a reduction in protein levels of
JunD (Fig. 2B); a result consistent with the gene expression data
(Fig. 2A) and the decrease in JNK activity noted after IL-7
withdrawal (Fig. 1B).
IL-7-dependent JNK activity drives glucose uptake
through the synthesis of HXKII
To investigate a functional consequence of JNK activity, D1
cells were deprived of IL-7 for 18 hours and IL-7 added back to
the culture with the addition of either PD169316, (p38 MAPK/
JNK inhibitor), MEK1/2 inhibitor, or wortmannin (PI3K
(Phosphoinositide 3-kinase) inhibitor). As an indicator of cell
metabolism, glucose uptake was measured using 2-DOG [39].
Figure 3A showed decreased glucose uptake in D1 cells that were
stimulated with IL-7 and incubated with PD169316, an inhibitor
of the p38/JNK pathway, but not with inhibitors of the MEK1/
ERK pathway or the PI3K pathway. To differentiate between the
p38 MAPK and JNK pathways, glucose uptake was then
measured in IL-7-stimulated D1 cells cultured with specific
inhibitors for JNK or p38 MAPK. Figure 3B demonstrates that
D1 cells incubated with a JNK inhibitor, but not a p38 MAPK
inhibitor, had decreased glucose uptake upon IL-7 addition. To
show that, upon IL-7 stimulation, JunD/AP-1 complexes
mediated the uptake of glucose, D1 cells were treated with JunD
siRNA and assayed for the uptake of 2-DOG. The efficacy of
siRNA knockdown of JunD mRNA (,60%) and protein (,50%)
are shown in later figures. Inhibition of JunD reduced the uptake
of glucose in IL-7-stimulated D1 cells to levels approaching those
observed in the cells cultured without IL-7 (Fig. 3C). Note that
background levels of 2-DOG uptake are indicated by the IL-7
deprived controls and are the point of comparison for the other
experimental samples. These results indicate that JNK and JunD/
AP-1 complexes were in part responsible for regulating the activity
of factors that promoted glucose uptake upon IL-7 stimulation.
In our previous study, we reported that HXKII gene expression
increased after 2 hours of IL-7 re-addition to deprived cells [39].
We also found that a STAT5-independent mechanism with
driving the synthesis of HXKII (Fig. S1 and Fig. 1A). Since the
gene expression of JunD was dependent upon JNK and IL-7
(Fig. 2A), it was possible that the increase of HXKII gene
expression that followed IL-7 re-addition was also associated with
the activity of JNK. Therefore, the synthesis of HXKII was
evaluated in D1 cells stimulated with IL-7 and treated with a JNK
inhibitor. Quantitative PCR results demonstrated that HXKII
synthesis was reduced by about 60% compared to vehicle control
upon treatment with JNK inhibitor (Fig. 4A). D1 cells incubated
with the p38 MAPK inhibitor showed little effect (Fig. 4A). This
data confirmed that the IL-7-driven increase in HXKII gene
expression is likely mediated by JNK. To establish a role for JunD-
containing AP-1 complexes in HXKII gene expression, D1 cells
were stimulated with IL-7 and treated with JunD siRNA. Shown
in Figure 4B is a representative experiment in which loss of JunD
reduced the IL-7-driven expression of HXKII. A graph alongside
shows that treatment with JunD siRNA reduced JunD mRNA
levels by approximately 60% as compared to the non-targeting
control siRNA. Hence, JunD/AP-1 complexes were contributing
to the synthesis of HXKII in response to IL-7.
The binding of JunD/AP-1 complexes to the AP-1 site on the
HXKII promoter wasexamined to validateour conclusions. To this
end,achromatinimmunoprecipitationassay(ChIP)wasperformed.
Nuclear lysates of D1 cells cultured with and without IL-7 for
18 hours were incubated with JunD antibody to immunoprecipitate
JunD-bound DNA. Quantitative PCR was then performed, using
primers specific to the AP-1 region on the HXKII promoter to
amplify a DNA sequence of approximately 150 base pairs. In
Figure 4C, we reported the cycle threshold (Ct) values, indicating
that amplification of the HXKII promoter DNA, immunoprecip-
itated with the JunD antibody, from IL-7-cultured cells, occurred 6
cycles faster than from IL-7 deprived cells and was thus significantly
performed with antibodies specific for c-Fos, c-Jun or Jun-D. Competition was also performed using 106, 1006or 10006excess unlabeled AP-1
probe or AP-1 mutant probe. Results (A, B, and C) are representative of three or more independent experiments (values in graphs are mean 6 SD).
doi:10.1371/journal.pone.0032262.g001
Figure 2. JNK activity promotes JunD expression. (A) Quantita-
tive PCR evaluation of JunD expression in the IL-7 dependent T-cell line,
D1. Cells were continuously cultured with IL-7 or without IL-7 for
18 hours, or withdrawn from IL-7 (18 hours) and then re-stimulated for
two hours (IL-7 Re-addition). Re-stimulated cells were untreated, treated
with DMSO (Vehicle Control), 20 mM JNK inhibitor (JNK inhibitor), or
20 mM p38 MAPK (p38) inhibitor. (***) indicates P,0.0001. (B) Western
blot analysis of JunD protein and p38 MAPK protein content, as loading
control, of whole cell lysates from D1 cells cultured as stated above.
Relative JunD protein indicates JunD protein levels normalized to p38
MAPK (loading control) and compared to the untreated, IL-7 re-addition
sample. Results (A, B) are representative of four independent
experiments (values in graphs are mean 6 SD).
doi:10.1371/journal.pone.0032262.g002
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was run on a non-denaturing agarose gel to demonstrate that more
HXKII promoter DNA was amplified from samples of D1 cells
cultured with IL-7. Controls for the reaction are the total DNA
inputs, showing equivalent amounts of starting materials. This
representative experiment confirms that JunD-containing AP-1
complexes bound to the AP-1 site within the HXKII promoter
region in an IL-7 dependent manner.
Bioinformatics Approach Reveals Novel IL-7 Induced
Genes Induced by AP-1/JunD
To identity novel IL-7-regulated genes whose synthesis was
driven by JunD/AP-1 complexes, we performed a bioinformatics
analysis. Previously, we identified a number of genes whose
expression was induced upon IL-7 stimulation or deprivation [31].
A comparison of these genes with potential JunD-targeted genes
(identified in a bioinformatics screen, see Methods and Figure S2
with Data S1) yielded a number of targets containing putative
JunD binding sites that were potentially IL-7-responsive. The
diagram, shown in Figure 5, organizes the information by
function. Of the three cell lines characterized, gene functions
were separated into suppressive (red) or supportive actions (green).
Many of the gene products identified were involved in signal
transduction, survival or adhesion (Fig. 5). Among these, JunD
emerged as a self-regulated and IL-7 dependent gene (Fig. 5).
Suppressive genes were generally involved in blocking inflamma-
tory processes (Fig. 5). The cell line databases assessed for potential
JunD target genes were also evaluated for functional homology,
whether inhibitory or stimulatory. The most significant gene
ontology terms, according to cell line, are listed in order by P-value
and are provided as Data S1. Gene ontology ID (GO), significance
by p-value, and the number of genes annotated with that term are
found in supplemental files. Also included under each cell line are
the number of annotated target genes and the number of target
genes for the specific cell line. This approach revealed that a
variety of functions can be ascribed to JunD-mediated transcrip-
tion, specifically, regulation of signal transduction, cell cycling and
cellular metabolic processes. Of those genes, ones initiated early in
the IL-7 signaling cascade, which could drive additional growth
pathways, were of interest for study.
Pim1 is an IL-7-Inducible Gene Product through the
Activity of AP-1/JunD
One of the genes that emerged from the bioinformatics analysis
as a JunD target and IL-7 dependent was the proto-oncogene,
Pim-1. Hence, Pim-1 was chosen for evaluation to validate the
bioinformatics approach and provide insight on a novel aspect of
the IL-7 signal. The repetitive blot in Figure 6A revealed
detectable levels of Pim-1 protein in D1 cells grown continuously
with IL-7 for 18–24 hours, while withdrawal of IL-7 for 2–
24 hours caused a decline in Pim-1. Next, we examined the effect
of JNK inhibition upon Pim-1 protein levels in D1 cells grown
with or re-stimulated with the cytokine. Our data in Figure 6B
indicates that the basal levels of Pim-1 protein expressed in D1
cells, continually growing in IL-7, were only slightly decreased by
inhibition of JNK; however, the increased amounts of Pim-1 that
were induced upon re-stimulation with IL-7 for 2 or 4 hours after
deprivation were almost completely inhibited by blocking JNK
Figure 3. A functional consequence of JNK/JunD signaling is
the IL-7 dependent uptake of glucose. (A) D1 cells continuously
cultured with or without IL-7 for 18 hours, or withdrawn (18 hours) and
then stimulated with IL-7 for four hours (IL-7 Re-addition), were
untreated or treated with DMSO (Vehicle Control), 20 mM MAPK
inhibitor, 20 mM PD169316, 20 mM MEK1/2 inhibitor or 5 nM PI3K
inhibitor, wortmannin. Glucose uptake was assessed by measuring the
accumulation of radiolabeled 2-DOG as stated in Methods. (*) indicates
P=0.0348. (B) D1 cells were treated similarly as those in (A) except that
cells were pulsed for two hours and specific inhibitors for JNK (20 mM)
or p38 MAPK (20 mM) were used. (*) indicates P=0.0342. (C) D1 cells
were cultured with or without IL-7 after introduction of non-specific
control (NT) or JunD siRNA as described in Methods. Glucose uptake
was assessed as above by measuring the accumulation of radiolabeled
2-DOG. (*) indicates P=0.0320. Results (A, B, and C) are representative
of three or more experiments performed (values in graphs are mean 6
SD).
doi:10.1371/journal.pone.0032262.g003
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part JNK-dependent, but that induction of Pim-1 protein upon IL-
7 re-addition was almost completely dependent upon JNK
signaling (Fig. 6B). To establish that JunD/AP-1 factors were
transducing the JNK signal that induced Pim1, we repeated the
experiment using JunD siRNA and observed a measureable
Figure 4. HXKII gene expression is dependent upon JNK/JunD signaling. (A) HXKII gene expression in the IL-7 dependent T cell line, D1, was
measured by quantitative PCR as described in Methods. Cells were cultured with or without IL-7, or after an IL-7 pulse for 2 hours (IL-7 Re-Addition),
in presence of a vehicle control, 20 mM JNK inhibitor, or 20 mM p38 inhibitor. RQ (Fold change)=2
2DDCt. (***) indicates P,0.001. (B) HXKII gene
expression in D1 cells cultured with or without IL-7 and the non-targeting control (NT) or JunD siRNA, as described in Methods, was measured as
above. (*) indicates P=0.0254. Efficacy of JunD siRNA upon JunD mRNA levels (right panel) was established through measuring total JunD gene
expression by quantitative PCR. (*) indicates P=0.0336. RQ (Fold change)=2
2DDCt. (C) Chromatin Immunoprecipitation (ChIP) was performed using
nuclear lysates from D1 cells cultured with or without IL-7 for 18 hours. Results from the quantitative PCR, reported as cycle threshold (Ct) values, are
shown in the table. The PCR-amplified 150 bp region of AP-1 promoter DNA from the HXKII gene was visualized by ethidium bromide staining in a
non-denaturing agarose gel. Input DNA is shown as equivalent starting materials. Results (A, B and C) are representative of three experiments
performed in triplicate (values in graphs are mean 6 SD).
doi:10.1371/journal.pone.0032262.g004
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when JunD expression was impaired. Levels of JunD protein in
these cells are shown for comparison.
These studies were followed by examining Pim-1 gene
expression in response to either JNK or AP-1/JunD inhibition.
In Figure 7A, re-addition of IL-7 caused an increase in Pim1
mRNA supporting that increase previously detected by protein
assay (Fig. 6B). Inhibition of JNK decreased the levels of Pim-1
mRNA in D1 cells stimulated with IL-7, while little or no effect
was observed in D1 cells continually grown in IL-7. Likewise, as
observed for protein levels of Pim-1, inhibition of JunD with
siRNA decreased Pim-1 gene expression in cells re-stimulated with
IL-7 after deprivation (Fig. 7B).
Proliferation of Primary Lymphocytes in Response to IL-7
Depends on JunD Activity
Our studies with the D1 cell line revealed the specifics of the IL-
7 signaling pathway from activation of JNK through induction of
the JunD/AP-1 transcription factors and increased gene expres-
sion of HXKII and Pim-1. The expected outcome of IL-7 signal
transduction through this pathway would be T-cell proliferation.
To examine this, we used our ex vivo expansion protocol [43] to
isolate IL-7-dependent primary T-cells. This expansion method is
needed because freshly isolated lymphocytes contain only a small
number of T-cells that proliferate in response to IL-7 (,10–20%,
Khaled, unpublished data). To confirm the results observed with
D1 cells, that JunD and Pim1 expression was dependent on the
Figure 5. Bioinformatics evaluation of IL-7 dependent gene expression transduced through JunD. Three cell lines (GM12878, Helas3,
and K562) were evaluated for genes containing putative JunD binding sites that are potentially IL-7-responsive, as described in Methods. Gene
functions were determined using gene ontology analysis as described in Methods, and were separated into suppressive (red) or supportive actions
(green).
doi:10.1371/journal.pone.0032262.g005
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inhibitor and assessed the effect upon protein levels of JunD and
Pim-1. Results in Figure 8A show that JNK inhibition resulted in
decreased JunD and Pim-1 proteins (34% and 64% respectively),
substantiating the data from D1 cells. Note that primary T-cells
under IL-7-deprived conditions cannot be evaluated because these
fail to expand and die in culture. To evaluate IL-7-driven
proliferation, we measured the incorporation of BrdU in CD4 and
CD8 T-cells. As shown in Figure 8B, continuous culture with IL-7
caused CD8 T-cell expansion (16%) to occur more rapidly as
compared to CD4 T-cells (2%) – an observation previously
published [16]. The addition of JunD siRNA had a modest
inhibitory effect (Fig. 8B). However, examining the proliferation of
Figure 6. Pim-1 protein is dependent on IL-7 and JNK/JunD. (A)
Immunoblot analysis of Pim-1 was performed. Whole cell lysates were
prepared from D1 cells cultured in the presence or absence of IL-7 for
the indicated time points. p38 MAPK was measured as a loading
control. (B) Immunoblot analysis of Pim-1 was performed. Whole cell
lysates were prepared from D1 cells cultured in the presence (+)o r
absence (2) of IL-7 and/or with JNK inhibitor (20 mM), or 2–4 hour IL-7
stimulation after 18 hour deprivation, alone, or with 20 mMJ N K
inhibitor. p38 MAPK was used as a loading control. (C) Whole cell
lysates of D1 cells were cultured for 52 hours with IL-7 in the presence
of non-targeting control (NT) or JunD siRNA, then cells were withdrawn
from IL-7 for 18 hours as described in Methods. A separate group was
also deprived of IL-7, and then re-stimulated with IL-7 for two hours in
the presence of siRNA (Re-addition). Whole cell lysates were subjected
to SDS-PAGE and immunoblotted for Pim-1, JunD, and p38 as loading
control. Tables indicate relative amounts of protein normalized to p38
content and shown relative to the IL-7 re-addition sample. Results are
representative of three experiments performed.
doi:10.1371/journal.pone.0032262.g006
Figure 7. IL-7 inducible Pim-1 gene expression is dependent on
JNK/JunD. (A) Pim-1 gene expression in the IL-7 dependent T cell line,
D1, was measured by quantitative PCR as described in Methods. D1
cells were cultured with or without IL-7 (+/2 IL-7), in the presence of a
vehicle control (Vehicle) or 20 mM JNK inhibitor (JNK Inh). In some
samples, after an 18 hour deprivation, IL-7 was added back to the
culture for 2 hours in the presence of a vehicle control (IL-7 Re-addition,
Vehicle) or 20 mM JNK inhibitor (IL-7 Re-addition, JNK Inh). (*) indicates
P=0.0104. (B) Quantitative PCR of Pim-1 gene expression was
performed using D1 cells cultured for 52 hours with IL-7 (+) and then
18 hours without IL-7 (2) in the presence of non-targeting control (NT)
or JunD siRNA. A separate group was also deprived of IL-7, and then re-
stimulated with IL-7 for two hours in the presence of siRNA (IL-7 Re-
addition). RQ (Fold change in gene expression normalized to b-
actin)=2
2DDCt. Results are representative of three experiments
performed in triplicate (values in graphs are mean 6 SD). (*) indicates
P=0.0140.
doi:10.1371/journal.pone.0032262.g007
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32262Figure 8. Inhibition of JunD Prevents IL-7 Induced Proliferation of Primary Lymphocytes. (A) Lymph node T-cells were isolated from WT
C57Bl/6 mice, cultured continuously with 150 ng/ml of IL-7 for 7 days (Continuous) or for 5 days, then deprived from IL-7 overnight, and IL-7 re-added
for 24 hours (Stimulation) and treated with vehicle (DMSO) or 20 mM JNK inhibitor as described in Methods. Whole cell lysates were prepared from T-
cells, subjected to SDS-PAGE and immunoblotted for Pim-1, JunD, and p38 MAPK as loading control. Tables indicate amounts of protein normalized
to p38 MAPK content and shown relative to the IL-7 (Continuous) sample. Results are representative of two experiments performed. (B, C)
Proliferation was measured by BrdU incorporation. Lymph node T cells were isolated from WT C57Bl/6 mice as described in (A) and treated with non-
targeting control (NT) or JunD siRNA as described in Methods. Cells were assessed for BrdU incorporation and surface expression of CD4 and CD8 as
determined by flow cytometric analysis of BrdU-PE and CD4- or CD8-PerCp fluorescence. Dot blots show percentages representing the population of
cells that are non-proliferating (BrdU negative), proliferating (BrdU positive), and CD4+ or CD8+ as indicated by the quadrants. Quadrants were
established using controls. Gating was performed to remove autofluorescent cells. Results are representative of duplicate samples.
doi:10.1371/journal.pone.0032262.g008
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32262CD4 and CD8 T-cells, re-stimulated with IL-7, revealed that
JunD inhibition reduced IL-7 driven growth by more than 60% -
more so for the actively dividing CD8 T-cells (from 13% to 5%)
(Fig. 8C). These results suggest that IL-7 signaling promotes T-cell
proliferation in part through JunD-mediated transcription of gene
products such as Pim-1 or HXKII.
In summary, we have shown that IL-7 promotes growth signals
through other transcriptional components in addition to STAT5.
We found that the JunD/AP-1 transcription factors are activated
in response to JNK and drive the synthesis of at least two essential
mediators of lymphocyte growth, HXKII and Pim-1, in response
to IL-7 stimulation. These results establish a novel approach
employing bioinformatics to discover new transducers of the IL-7
metabolic and proliferative signals.
Discussion
Our results suggest that IL-7 in part contributes to the
metabolism and growth of T-cells by promoting HXKII and
Pim-1 gene expression through the JNK activation of JunD/AP-1.
This conclusion was reached by finding that JNK was active in
response to IL-7, and that IL-7 induced the binding of AP-1
transcription factors, containing JunD, to DNA sequences such as
the HXKII promoter. Using a bioinformatics approach to
discover previously unrecognized JunD gene targets that were
IL-7-responsive, we identified Pim-1. Confirmation that Pim-1
expression was IL-7- and JunD-dependent, validated the bioinfor-
matics results. Physiological relevance of our findings was
established when inhibition of JNK in primary lymphocytes
decreased the levels of Pim-1 and JunD and inhibition of JunD
prevented the proliferation of CD8 T-cells stimulated with IL-7.
This work achieves the goal of demonstrating that other regulators
of gene expression, in addition to the JAK/STAT5 pathway, can
respond to the IL-7 signal in T-cells and indicates that a
bioinformatics approach can be used to discover novel IL-7 signal
transducers.
To support T-cell growth, IL-7 signaling leads to the activation
of transcription factors, such as STAT5. STAT5 can mediate T-
cell survival by inducing anti-apoptotic proteins of Bcl-2 family
[44,45]. STAT5 also promotes glucose metabolism by enabling
GLUT1 trafficking to the cell surface [38]. However, we found
that the IL-7-mediated increase of HXKII gene expression used a
STAT5 independent mechanism to regulate glucose uptake in T-
cells. We identified JunD-containing AP-1 complexes as key
factors that controlled the synthesis of HXKII in response to IL-7.
Pim-1 is also a recognized gene transcribed by STAT5 [46] and a
possible JunD-target. We found that T-cells deprived and then re-
stimulated with IL-7, which mimics the in vivo conditions in which
T-cells encounter IL-7, immediately increased Pim-1 levels in a
JunD/AP-1 dependent manner. This is consistent with the
proliferative function of Pim-1, since it phosphorylates and induces
the activity of proteins involved in cell cycling, including Cdc25A
[47] and Skp2 [48]. Our conclusions are supported by the fact that
Pim-1 is an effector of the IL-7 signaling pathway, as its expression
reconstituted thymic cellularity in IL-7 deficient mice [49], and
that Pim-1, 2 and 3 are required for proliferation of peripheral T-
cells [50].
JunD was initially described as a negative regulator of
proliferation. Early studies showed that over expression of JunD
in immortalized fibroblasts increased the numbers of cells in the
G0/G1 phase of the cell cycle, promoting growth arrest [30].
JunD also suppressed transformation by Ras [30]. Immortalized
cells lacking JunD had higher levels of cyclins and increased
proliferation, but also were more sensitive to death-inducing
agents, suggesting that JunD could have both negative and positive
effects upon cell growth [51,52]. Concerning the latter activity,
JNK and JunD were shown to work with NF-kB to increase the
expression of the caspase inhibitor, cIAP-2 [52]. While these
studies were performed using immortalized cells and fibroblasts,
the evaluation of JunD activity in lymphocytes revealed different
results and demonstrated that JunD activity can be cell specific.
JunD over expression did not protect lymphocytes from apoptosis
and caused reduced growth and activation, while JunD
2/2 T-cells
hyperproliferated upon stimulation [53]. These findings seemed in
apparent conflict with our data that HXKII, a key enzyme in the
glycolytic pathway, was a JunD target gene. To explain this, we
performed a bioinformatics evaluation of potential JunD-regulated
genes and found that many critical effectors of cell signaling and
growth (like Pim-1), survival (like Bcl-2), and metabolism were
possible JunD targets. Further, we found that inhibition of JunD
impaired the proliferation of T-cells in response to IL-7. While,
JunD remains a negative regulator of growth in many cells, like
intestinal epithelial cells in which JunD repressed gene expression
of cyclin dependent kinase 4 (CDK4) [54], in IL-7-pulsed T-cells,
as shown in our studies, JunD promotes the expression of essential
growth effectors.
Regulation of JunD gene expression is not typical of other AP-1
components. Contrary to results with other AP-1 proteins, JunD
protein levels were detected in quiescent immortalized cells; JunD
protein then initially declined upon serum stimulation and later
steadily increased [30]. Coupled to the constitutive activity of the
JunD promoter, this suggests that JunD may be controlled by
different post-transcriptional or post-translational mechanisms. As
example, the JunD transcript is intronless, is G/C rich, has a long 59
untranslated region (UTR) and produces two isoforms, a full-length
and truncated form (reviewed in [55]). Moreover, the presence of a
unique post-transcriptional control element (PCE) and the potential
interaction with RNAhelicaseA (RHA) suggests that JunD could be
efficiently translated under the right growth conditions [56]. Post-
translational modifications also contribute to the activity of JunD in
different cellular environments. JunD is poorly ubiquitinated and
has a long half-life [57]. The JunD transcript is also positively
regulated by JNK activity [58], as we have shown in the IL-7-
dependent D1 cells. In fact, JNK could stimulate an auto-regulatory
loop that controls the gene expression of JunD.
In summary, JunD emerges as an important transducer of the
IL-7 signal in T-cells and, along with the JAK/STAT pathway,
could promote gene expression to drive survival and growth when
cells are stimulated with IL-7. The importance of this conclusion is
appreciated when considering that T-cells normally exist in an IL-
7-limited environment (with picograms levels of the cytokine
normally detected in serum [59]). To be stimulated, T-cells must
traffic to IL-7-containing tissues. When a T-cell receives an lL-7
signal, the JNK/JunD pathway may function to enhance the
JAK/STAT mechanism and induce expression of genes like
HXKII and Pim-1 as a rapid response to the initial growth signal.
Because the therapeutic use of IL-7 involves application of
superphysiological dosing of the cytokine that is very different
from the in vivo state of limited IL-7 availability, there is a need to
better understand the consequences of IL-7 signal transduction
and the impact upon gene expression in T-cells. The fact that the
JNK/JunD pathway can have positive outcomes in IL-7
dependent T-cells highlights the need for continued research in
this area. The bioinformatics approach presented could provide a
means to identify potential gene expression changes that result
from activation of JunD/AP-1 complexes in the context of IL-7
signaling that can be tested for validation in different animal
models of immunological responses.
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Mice, Cell Lines and Culture Reagents
C57Bl/6 mice were purchased from Jackson Laboratory (Bar
Harbor, Maine) and housed at the University of Central Florida,
Orlando, FL. Mice were used in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocol was approved by
the Institutional Animal Care and Use Committee at the
University of Central Florida (Assurance # A4135-01). All efforts
were made to minimize suffering. The IL-7 dependent T cell line,
D1, was established from pro-T lymphocytes isolated from a
p53
2/2 mouse as previously described [31]. Since its establish-
ment in 1997, the D1 cell line has been used to study regulatory
pathways controlled by IL-7 [19,33,36,39,60]. D1 T-cells were
grown in RPMI 1640, 10% fetal bovine serum (FBS), 5%
Penicillin/Streptomyocin (Fisher), 0.1% B-mercaptoethanol (In-
vitrogen) (complete medium) and 50 ng/mL IL-7 (Peprotech).
Early passages of D1 cells were frozen as stocks and cells used at
less than 10 passages from stocks. Primary lymph node (LN) T cells
were isolated from 8- to 12-week-old C57Bl/6 mice as previously
described [43]. To enrich for IL-7 dependent cells, we used our
published method of ex vivo expansion, culturing LN T cells with
150 ng/mL IL-7 for 5 days [43]. Reagents used as described in
Figure Legends include: JNK inhibitor II (Calbiochem, 20 mM),
p38 MAPK inhibitor (Calbiochem, 20 mM), Wortmannin (Cal-
biochem, 5 nM), PD169316 (Calbiochem, 20 mM), MEK1/2
inhibitor (Calbiochem, 20 mM) and STAT5 inhibitor (Calbio-
chem, 50 mM).
Plasmids and Nucleofection for Transient Gene
Expression
Generation of the chimeric IL-4 receptor/IL-7 receptor
plasmids were previously described [60] and pcDNASTAT5a-
CA was a kind gift from Dr. Wenqing Li, NCI-Frederick. To
transiently express the plasmids, T-cells were ‘‘nucleofected’’ using
the Murine T-cell Nucleofection kit (Amaxa), following the
manufacturer’s protocol. Briefly, 1610
6 D1 cells were incubated
with (4 mg) plasmid DNA in 100 ml of the mouse T-cell solution,
and electroporated with the specific program optimized for mouse
T-cells. Nucleofected D1 cells were incubated in the supplemented
media with or without IL-7 for 4–8 hours prior to analysis. In D1
cells nucleofection efficiency averaged approximately 40–50%
expression of the target gene with viabilities ranging 60–80%.
Glucose Uptake Assay
Cells were incubated in glucose-free, serum-free RPMI 1640
supplemented with or without IL-7 for 1 hour. 2-Deoxy-D-[3H]
glucose (2-DOG)(2 mCi/reaction) (Sigma) was added for 3 min.
Reactions were stopped by adding 250 ml of ice-cold 0.3 mM
phloretin (Sigma). Cells were then centrifuged through a cushion
of 10% bovine serum albumin, and lysed with 0.1% Triton X-100.
Radioactivity was measured with scintillation counter (LS6500,
Beckman Coulter).
Real Time PCR
Ten million cells per experimental condition were re-suspended
in 1 ml of TRIzol reagent (Invitrogen). Total RNA was extracted
from the cells using the reagent according to the manufacturer’s
instructions. Each cDNA template was synthesized from total
RNA by reverse transcription with iScript cDNA Synthesis kit
(BioRad) according to manufacturer’s instructions. Quantitative
analysis of cDNA amplification was assessed by incorporation of
SYBR Green (ABI) into double-stranded DNA. Primer sets were
used as follows: for mouse Pim-1: 59-CCC GAGCTATT-
GAAGTCTGA-39,5 9-CTGTGCAGATGGATCTCA GA-39
(sense and antisense, respectively) [61], for mouse JunD: 59-
ATGGACACGCAGGAGCGCAT-39 and 59-AGCAGCTGG-
CAGCCGCTGTT-39 (sense and antisense, respectively [62], for
mouse HXKII: 59-CACTGGGTACTAAGGCTCAA-39 and 39-
CGGAGTTGTTCTGCTTTGGA-59 [39], and for b-Actin: 59-
GAAATCGTGCGTGACATCAA AG-39 and 59-TGTAGTTT-
CATGGATGCCACAG-39 (sense and antisense, respectively)
[63]. Reactions contained Fast SYBR Green Master mix (16),
b-Actin primers (50 nM), or Pim-1 or JunD primers (100 nM),
and 3–4 mg cDNA template. Thermal cycling conditions were as
follows: enzyme activation for 20 seconds at 95uC, followed by 40
cycles of 3 seconds at 95uC, and 30 seconds at 62uC at annealing
and extension temperatures. All cDNA samples were processed
using the ABI Fast 7500 and analyzed using ABI Sequence
Detection Software version 1.4. The difference in mRNA
expression was calculated as follows: fold change=2
2DDCt, DDCt
is equal to the change in DCt values over time after normalization
to b-actin.
Detection of Proteins by Immunoblotting
For preparation of whole cell lysates, 20–25610
6 D1 cells (per
experimental sample) were lysed using the Cell Lysis buffer (Cell
Signaling) in the presence of protease and phosphatase inhibitors
(Roche). Lysates were immunoblotted for Pim-1 and JunD as
described below. For immunoblotting, whole cell lysate samples
were run in 12% SDS-PAGE gels, and proteins transferred to
nitrocellulose membranes (Invitrogen) following manufacturers’
protocols. Membranes were washed and probed with primary
antibodies (see below) and incubated with horseradish peroxidase
(HRP)-conjugated (Santa Cruz) or fluorescence-conjugated sec-
ondary antibodies (LICOR). Signal was detected using either
chemiluminescent substrate (SuperSignal West Fempto; Thermo-
Sci) or the LICOR Odyssey detection system. The primary
antibodies used in this study were as follows: a mouse monoclonal
antibody against Pim-1 (Abcam), and rabbit polyclonal antibodies
against p38 (Santa Cruz Biotechnology), and JunD (Abcam).
JunD Inhibition by Small Interfering RNAs (siRNAs)
Four million D1 cells (per experimental condition) were treated
with JUND1 SMART pool siRNA (Dharmacon) and Accell
delivery media (Dharmacon) supplemented with 1% FBS, and IL-
7 (50 ng/ml) for 52 hours. After 52 hours, cells were washed and
re-plated in media containing the siRNA alone, for 18 hours with
or without IL-7. In addition, a subset of IL-7 deprived cells was re-
pulsed with the cytokine. SMART pool siRNA contains four
sequence variations of siRNAs to eliminate non-specific interac-
tions. Non-targeting siRNA (NT siRNA) and NT siRNA,
containing a FAM reporter, were used as controls and to
determine delivery efficiency, respectively.
Detection of JNK Activity
Whole cell lysates from 10610
6 D1 cells (per experimental
sample) were prepared using the Kinase Extraction Buffer
provided within the JNK kinase assay kit (KinaseSTAR JNK
Activity Assay Kit, BioVision) and assayed for protein concentra-
tion by absorbance at 280 nm (Nanodrop 8000). To measure JNK
activity, cell lysates were pre-cleared with Protein A/G Sepharose
beads (Santa Cruz) and then incubated with the kit provided JNK-
specific antibody and agarose beads to pull down JNK. Phospho-c-
Jun was used as a substrate to measure JNK activity following the
manufacturer’s protocol. Total JNK protein in lysates was
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the immunoblot procedure described above.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assay was performed using the ChIP-IT kit (Active Motif)
according to manufacturer’s protocol. Briefly, 100610
6 D1 cells
were incubated overnight with or without IL-7, and treated with
37% formaldehyde to crosslink protein to DNA. Cells were then
treated with the kit-provided lysis buffer supplemented with
protease inhibitors and dounce homogenized. Nuclear pellets were
sonicated and pre-cleared using the Protein G beads provided
within the kit. Pre-cleared chromatin was incubated with anti-
JunD antibody (Abcam) and immunoprecipitated using Protein G
beads according to the manufacturer’s protocol. DNA was eluted
and purified. To determine the DNA sequence to which JunD
bound, PCR analysis of the DNA was performed using AP-1
primers for the HXKII promoter sequence (Primer3 software):
forward Primer 59GGGCTCTAGGCGCTGATT39 and reverse
Primer: 59GGAGTTGGTGCAACAATGTG39. PCR products
were analyzed by non-denaturing agarose gel (1%) electrophoresis.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extraction and EMSA were performed according to the
method described by Jaganathan et al. [64] and a modified
Dignam protocol [65]. Briefly, 60610
6 cells were washed and cell
lysates prepared with hypotonic buffer (20 mM HEPES (pH 7.9),
1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 1 mM Na4P2O7,
0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin, 1 mM
antipain, and 1 mM DTT). NP-40 was added to a final
concentration of 0.2% and the solution was centrifuged. The
supernatants were retained as cytosolic controls and the nuclear
pellets lysed with hypertonic extraction buffer (20 mM HEPES
(pH 7.9), 0.42 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, 20 mM NaF, 20% glycerol, 1 mM Na3VO4, 1 mM
Na4P2O7, 0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin,
1 mM antipain). The nuclear fractions were then recovered by
centrifugation. Transcription factors bound to specific DNA
sequences were examined by EMSA. Normalized extracts,
containing 3–8 mg of total protein, were incubated with a
double-stranded
32P-radiolabeled AP-1 oligonucleotide probe
(Santa Cruz) prepared by radiolabeling the AP-1 probe with
[a
32P]dCTP (3000 Ci/mmol) and [a
32P]dATP (3000 Ci/mmol).
Protein-DNA complexes were resolved by non-denaturing poly-
acrylamide gel electrophoresis (PAGE) and detected by autoradi-
ography. To establish the specificity of the AP-1 probe, unlabeled
AP-1 oligonucleotides or mutant AP-1 nucleotides (Santa Cruz)
were incubated with nuclear extracts for 15 min before incubation
with radiolabeled probes. To identify components of the AP-1
transcription factor in the DNA–protein complex shown by
EMSA, we used protein-specific supershift antibodies, c-Fos, c-Jun
and JunD (Active Motif), to detect the formation of a supershift
DNA–protein complex. These antibodies were incubated with the
nuclear extracts for 30 min at room temperature before
incubation with radiolabeled probe.
Analysis of JunD ChIP-seq Data
The JunD ChIP-seq (chromatin immunoprecipitation followed
by high throughput parallel sequencing) data for three cell lines,
GM12878, Helas3, and K562, was downloaded from http://
hgdownload.cse.ucsc.edu/goldenPath/hg18/encode DCC/wgEn-
codeYaleChIPseq/. Narrow peaks provided by this website were
used as the binding regions of JunD. These narrow peaks are
regions enriched with JunD binding segments in ChIP-seq
experiments, and are selected with a false discovery rate [66] of
0.001. In total, 12958, 45893, and 1500 JunD binding regions
were obtained from the GM12878, Helas3, and K562 cell lines,
respectively. These JunD binding regions were compared with all
annotated refseq genes in the human genome. By assuming that
the genes closest to the above binding regions were target genes of
JunD, we obtained 6754, 15577, and 1643 target genes in the
above three cell lines, respectively. For example, we obtained 1643
target genes in the K562 cell line with only 1500 binding regions
because some binding regions were located in multiple annotated
genes. To understand the function of these target genes, we
performed gene ontology analysis by using the GOTermFinder
software [67]. Results are found in supplemental files, Figure S2
and Data S1. A previous cDNA array, using IL-7 dependent D1
cells [31], identified 179 genes that were immediate responders to
a two hour pulse with IL-7. We found that 116 out of the 179 IL-
7-responsive genes were target genes of JunD in the three cell lines.
However, 108 out of the 116 genes are not annotated.
Proliferation Assay for Primary Lymphocytes
Five to ten million primary LN T-cells, enriched by 5 day
culture with IL-7 and treated with control or JunD siRNA as
described above, were examined for proliferative capacity.
Viability of cultured cells was determined based on cell shrinkage
and granularity by gating on FSC/SSC parameters acquired by
flow cytometry (Accuri C6 Flow Cytometer). IL-7-cultured
primary T-cells treated with siRNAs were pulsed with 10 mM
BrdU for 48 hours. DNA synthesis was evaluated through BrdU
incorporation, using a PE-tagged, anti-BrdU antibody for
detection of DNA content with a commercially available kit
according to manufacturer’s protocol (BD Biosciences). Surface
expression of CD4 and CD8 on the primary T cells were assessed
by flow cytometry using the following conjugated antibodies:
PerCP-anti-CD4 (clone RM4-5), and PerCP-anti-CD8 (clone 53-
6.7) (BD Biosciences). Cells were incubated with antibodies for
20 min on ice, washed in RPMI+10% FBS, prior to BrdU
analysis, and analyzed by flow cytometry on a C6 flow cytometer
(Accuri).
Statistics
Statistical analysis and significance was determined using Prism
5 (Graphpad) for Windows, Version 5.02.
Supporting Information
Figure S1 STAT5 does not promote HXKII gene expres-
sion or glucose uptake in response to IL-7. (A, B) D1 cells
were nucleofected with pcDNA (empty vector) or constitutively
active STAT5a-CA (A) and evaluated for HXKII gene expression
using quantitative PCR or (B) glucose uptake as described in
Methods. Results are representative of two independent experi-
ments performed in triplicates (values in graphs are mean 6 SD).
(C) Quantitative PCR evaluation of HXKII gene expression in D1
cells after culture with or without IL-7 for 18 hours, or with IL-7
in the presence of a STAT5 inhibitor (50 mM) for 18 hours. RQ
(Fold change in gene expression normalized to b-actin)=2
2DDCt.
(*) indicates P value of ,0.05.
(TIF)
Figure S2 Identified JunD target genes in the three cell
lines. JunD-regulated gene targets were identified by ChIP-seq as
described in Methods. The top three most significant gene
ontology terms that are at least at level 5 for each group of target
genes are provided when they are available. For each term, a gene
ontology term ID is provided, followed by the p-value of
significance, and the number of target genes annotated with the
JunD Promotes IL-7-Dependent Lymphocyte Growth
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of annotated target genes and the number of target genes for the
specific cell line.
(TIF)
Data S1 The list of target genes in the three cell lines
and their shared function shown in Figure S2 are
provided in the supplemental file.
(XLS)
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